Abstract
The type II collagen induced arthritis model was used to evaluate the efficacy of tissue inhibitor of metalloproteases (TIMP) in suppressing the disease in DBA/1 mice. Treatment began following the first clinical manifestations of the disease state. Clinical observations, histological and radiographic findings show a decreased incidence of joint erosion in the treated population relative to the controls. It is concluded that systemic administration of recombinant human TIMP suppresses the pathology of type II collagen induced arthritis.
Similar content being viewed by others
References
J. M. Stuart, A. S. Townes, and A. H. Kang, Ann. Rev. Immunol.2, 199–218 (1984).
J. M. Stuart, W. C. Watson and A. H. Kang, FASEB J.2, 2950–2956 (1988).
G. P. Stricklin and H. G. Welgus, J. Biol. Chem.258, 12252–12258 (1983).
D. F. Carmichael, A. Sommer, R. C. Thompson, D. A. Anderson, C. G. Smith, H. G. Welgus and G. P. Stricklin, Proc. Natl. Acad. Sci. USA,83, 2407–2411 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carmichael, D.F., Stricklin, G.P. & Stuart, J.M. Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice. Agents and Actions 27, 378–379 (1989). https://doi.org/10.1007/BF01972827
Issue Date:
DOI: https://doi.org/10.1007/BF01972827